首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Evaluation of Vancomycin Population Susceptibility Analysis Profile as a Predictor of Outcomes for Patients with Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus
【2h】

Evaluation of Vancomycin Population Susceptibility Analysis Profile as a Predictor of Outcomes for Patients with Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus

机译:万古霉素易感性分析概况评估作为耐甲氧西林金黄色葡萄球菌感染性心内膜炎患者预后的指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA IE) is associated with high morbidity and mortality. Vancomycin continues to be the primary treatment for this disease. The emergence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA), defined as a modified population analysis profile (PAP) of ≥0.9, may affect patient outcomes. The objective of this study was to evaluate the relationship of vancomycin subpopulation susceptibility and the clinical outcomes of MRSA IE. We conducted a retrospective cohort study of patients treated with vancomycin for MRSA IE from 2002 to 2013 at the Detroit Medical Center. A modified PAP was used to measure the vancomycin PAP MIC and the PAP-to-area under the curve (AUC) ratio. Treatment failure was defined as bacteremia for ≥7 days or death attributed to MRSA. Classification and regression tree (CART) analysis was used to select a failure breakpoint between the PAP-AUC ratios and the PAP MIC. A total of 202 patients were included in the study. Twenty-seven percent of the patients had left-sided IE, 19% of the strains were hVISA, and 70% of the strains were staphylococcal cassette chromosome mec element (SCCmec) type IV. Overall treatment failure was observed in 64%; 59% had persistent bacteremia, and the 30-day attributable mortality rate was 21%. The CART breakpoint between failure and success in terms of the PAP-AUC ratio was 0.9035. On logistic regression analysis, intensive care unit (ICU) admission (adjusted odds ratio [aOR], 2.8; 95% confidence interval [CI], 1.5 to 5.2) and a PAP MIC of ≥4 mg/liter (aOR, 3.2; 95% CI, 1.3 to 8.4) were associated with failure (P = 0.001 and 0.015, respectively). A PAP MIC of ≥4 mg/liter and ICU admission were significant for treatment failure for patients with MRSA IE. The PAP-AUC ratio of ≥0.9035 predicted failure consistent with the hVISA definition. The role of population MIC analysis in predicting outcome with MRSA infections warrants further investigation.
机译:耐甲氧西林金黄色葡萄球菌(MRSA IE)引起的感染性心内膜炎与高发病率和高死亡率相关。万古霉素仍然是该疾病的主要治疗方法。万古霉素中间型金黄色葡萄球菌(hVISA)的定义为改良的人群分析谱(PAP)≥0.9,可能会影响患者的预后。这项研究的目的是评估万古霉素亚群易感性与MRSA IE的临床结局之间的关系。我们于2002年至2013年在底特律医学中心对万古霉素治疗MRSA IE的患者进行了回顾性队列研究。修改后的PAP用于测量万古霉素PAP MIC和曲线下(AUC)比下的PAP面积。治疗失败定义为≥7天的菌血症或MRSA导致的死亡。使用分类和回归树(CART)分析来选择PAP-AUC比率和PAP MIC之间的故障断点。该研究总共包括202名患者。 27%的患者患有左侧IE,其中19%的菌株为hVISA,70%的菌株为IV型葡萄球菌盒式染色体mec元件(SCCmec)。总体治疗失败率为64%; 59%患有持续性菌血症,30天归因死亡率为21%。根据PAP-AUC比率,失败和成功之间的CART断裂点为0.9035。在逻辑回归分析中,重症监护病房(ICU)入院(调整后的优势比[aOR],2.8; 95%置信区间[CI],1.5至5.2)和PAP MIC≥4mg / L(aOR,3.2; 95) %CI(1.3到8.4)与失败相关(分别为P = 0.001和0.015)。 MRSA IE患者的PAP MIC≥4 mg / L和入ICU对治疗失败很重要。 ≥0.9035的PAP-AUC比值预测的故障与hVISA定义一致。人群MIC分析在预测MRSA感染结局中的作用值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号